Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121565 | 0.93 | PTGS2 (0.39) | ESR1PTGS2AKR1C3AKR1C2TDP1 | |
| SCHEMBL10121509 | 0.91 | NAAA (0.42) | PTGS2AKR1C3AKR1C2TDP1L3MBTL1 | |
| SCHEMBL10144533 | 0.90 | MTNR1A (0.39) | HTR1AHTR1BPTGS2AKR1C3AKR1C2 | |
| SCHEMBL554978 | 0.89 | PTGS2 (0.41) | PTGS2AKR1C3AKR1C2TDP1L3MBTL1 | |
| SCHEMBL12135559 | 0.89 | PTGS2 (0.43) | ESR1PTGS2AKR1C3AKR1C2TDP1 | |
| SCHEMBL13199789 | 0.85 | MTNR1A (0.41) | PTGS2CA2AKR1C3AKR1C2TDP1 | |
| SCHEMBL12136650 | 0.85 | MTNR1A (0.37) | PTGS2AKR1C3AKR1C2TDP1L3MBTL1 | |
| SCHEMBL13206091 | 0.84 | PTGS2 (0.38) | PTGS2AKR1C3AKR1C2TDP1L3MBTL1 | |
| SCHEMBL555342 | 0.83 | PTGS2 (0.42) | PTGS2TDP1L3MBTL1 | |
| SCHEMBL12135489 | 0.83 | PTGS2 (0.38) | PTGS2AKR1C3AKR1C2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | HTR1A 515/4885HTR1B 1126/4885ESR1 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.